En los laboratorios de la Universidad McMaster, en Canadá, los científicos han encontrado en la tierra misma —fuente de los primeros antibióticos modernos— una molécula que ataca a las bacterias resistentes por una vía que ningún fármaco conocido ha recorrido antes. La manikomicina no asalta los flancos que las bacterias llevan décadas aprendiendo a defender, sino que obstruye la salida de sus fábricas de proteínas, paralizando su maquinaria vital desde adentro. Este hallazgo, publicado en Nature, no solo ofrece un candidato terapéutico prometedor contra patógenos como la Salmonella y la E. co
Noticias Venevisión
· Jun 04, 2026
· health
· 2 min de leitura
High
Apuração: Verificado
McMaster researchers discover manikomicin, antibiotic with novel mechanism against resistant bacteria
◉
Health & Medicine
2834 artigos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% correspondência
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% correspondência
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% correspondência
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% correspondência
Functional Medicine Shifts Focus to Patient as Active Participant in H…
El País · 90% correspondência
Cobertura Relacionada
La Razón · Aug 24
Expertos advierten sobre la enfermedad mano-pie-boca, infección viral frecuente en verano
La enfermedad mano-pie-boca, causada por enterovirus, es una infección infantil muy contagiosa pero generalmente leve qu…
La Vanguardia · Aug 24 Investigadores crean virus con IA y disparan alertas sobre bioseguridadInvestigadores de Stanford utilizaron IA para crear 16 virus bacteriófagos sintéticos, generando preocupaciones sobre la…
OkDiario · Aug 24 La inflamación aguda es necesaria; el problema surge cuando se cronificaUna farmacéutica explica que la inflamación aguda es esencial para la defensa del organismo, pero cuando se cronifica se…
The Objective · Aug 24 El chikungunya triplica sus casos en España con 119 positivos detectados este añoEspaña registra 119 casos de chikungunya en 2026, triplicando los 42 del año anterior, todos importados pero elevando la…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Canadian discovery of manikomicin antibiotic with novel mechanism addresses global antimicrobial resistance, potentially shifting pharmaceutical innovation leadership and reducing dependency on existing treatments.
Escalation Risk
low
Confidence
HIGH
Canada
Global (all nations dependent on antibiotics)
Developing nations with high antimicrobial resistance burden
Pharmaceutical manufacturing hubs (US, EU, India, China)
Strengthens Canada's biomedical research prestige and soft power; potential competitive advantage for North American pharmaceutical companies in antibiotic development; reduces global reliance on aging drug classes; may shift R&D investment patterns toward novel mechanisms over incremental improvements.
Similar to Fleming's 1928 penicillin discovery, which revolutionized medicine and established Western scientific leadership in pharmaceuticals for decades; demonstrates importance of fundamental research in addressing existential health threats.
Lente Econômica
📈
McMaster University's discovery of manikomicin, a novel antibiotic with unprecedented mechanism against drug-resistant bacteria, signals potential long-term pharmaceutical innovation and reduced healthcare costs from antibiotic-resistant infections.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical services
Agricultural sector (reduced antibiotic use in livestock)
Food production and safety
Consumers benefit from improved treatment options for serious bacterial infections, potentially lower healthcare costs from reduced complications of resistant infections, and decreased antibiotic overuse in food production leading to safer food supply.
Governments may accelerate antibiotic approval pathways for novel mechanisms; increased R&D funding for antimicrobial resistance solutions; potential regulatory changes for agricultural antibiotic use; international coordination on antibiotic stewardship programs.